A federal district judge in Illinois has dismissed a Chicago hospital’s apparently successful lawsuit challenging its termination from the 340B [...] …
Year: 2023
A group of Senate Republicans recently urged federal regulators to withdraw a plan to change the definition of a drug’s [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
An influential drug industry trade group recently urged a federal judge to rule on its suit against Louisiana’s 340B contract [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The Arkansas Insurance Department (AID) recently asked a federal district judge to dismiss Novo Nordisk’s lawsuit that challenges Arkansas’ state [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A federal district judge in South Carolina late today struck down the 340B program’s patient definition, as federal regulators described [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Medicare Part B will continue to pay hospitals for 340B drugs at the rate of average sales price (ASP) plus [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Medicare issued a final rule today to implement a $9 billion lump sum payment to 340B hospitals and to cut [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Forty-four health systems and hospitals sued federal healthcare agencies over their recent decision to end a 340B COVID-related registration flexibility [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Organon, a Merck spinoff with a focus on women’s health, yesterday became the sixth drugmaker to loosen or end its [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
The Centers for Medicare & Medicaid Services (CMS) has issued a final rule that goes into effect on January 1, 2024 that changes the way Direct and Indirect Remuneration (DIR) fees are collected. To understand the impact of this change, let’s review some background on DIR fees:
What are DIR Fees?
DIR fees are a type of fee imposed on pharmacies, particularly those that participate in Medicare Part D. DIR fees are a complex and often controversial aspect of the pharmacy reimbursement system.
How do DIR Fees work?
DIR fees are essentially retroactive price adjustments that are made by pharmacy benefit managers (PBMs) or Medicare Part D plan sponsors to pharmacies after a prescription has been dispensed to a Medicare beneficiary. These adjustments in almost all cases will decrease the reimbursement paid to the pharmacy for a particular prescription.